Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 11/20 | 0.73 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108297 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8020647 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8716402 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8573691 | 0.90 | SRD5A2 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL1108300 | 0.90 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL24503471 | 0.90 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9233678 | 0.90 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL14477868 | 0.90 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL14536870 | 0.90 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL790006 | 0.90 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563728-B2 | Process for the preparation of Dutasteride | AUROBINDO PHARMA LTD. (IN) | 2013-10-22 | — | — | US | disclosed |
| US-8563728-B2 | Process for the preparation of Dutasteride | AUROBINDO PHARMA LTD. (IN) | 2013-10-22 | — | — | US | disclosed |
| US-20120157683-A1 | PROCESS FOR THE PREPARATION OF DUTASTERIDE | AUROBINDO PHARMA LTD (IN) | 2012-06-21 | — | — | US | disclosed |
| US-20120157683-A1 | PROCESS FOR THE PREPARATION OF DUTASTERIDE | AUROBINDO PHARMA LTD (IN) | 2012-06-21 | — | — | US | disclosed |
| US-6114345-A | Phenylsubstituted 4-azasteroid fluoroderivatives | PHARMACIA & UPJOHN, S.P.A. (IT) | 2000-09-05 | — | — | US | disclosed |
| EP-0902790-B1 | PROCESS FOR PREPARING STEROIDS HAVING A CARBOXAMIDE SIDE-CHAIN | PHARMACIA & UPJOHN SPA (IT) | 2000-08-16 | — | — | EP | disclosed |
| EP-0793671-B1 | PHENYLSUBSTITUTED 4-AZASTEROID FLUORODERIVATIVES | PHARMACIA & UPJOHN SPA (IT) | 2000-02-09 | — | — | EP | disclosed |
| US-5922728-A | N-(PHENYLPERFLUOROALKYL)-3-OXO-4-AZA-5ALPHA-(ANDROSTANE OR ANDROST-1-ENE)-17BETA-CARBOXAMIDE DERIVATIVES, METHODS OF SYNTHESIZING THEM AND THEIR USE FOR TREATING PROSTATIC HYPERPLASIA | PHARMACIA & UPJOHN, S.P.A. (IT) | 1999-07-13 | — | — | US | disclosed |
| EP-0902790-A1 | PROCESS FOR PREPARING STEROIDS HAVING A CARBOXAMIDE SIDE-CHAIN | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-03-24 | — | — | EP | disclosed |
| US-5846976-A | Androstenone derivative | GLAXO WELLCOME INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1997040062-A1 | PROCESS FOR PREPARING STEROIDS HAVING A CARBOXAMIDE SIDE-CHAIN | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-10-30 | — | — | WO | disclosed |
| EP-0793671-A1 | PHENYLSUBSTITUTED 4-AZASTEROID FLUORODERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-09-10 | — | — | EP | disclosed |
| WO-1997010257-A1 | PHENYLSUBSTITUTED 4-AZASTEROID FLUORODERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-03-20 | — | — | WO | disclosed |
| US-5565467-A | 17-BETA-N-(2,5-BIS(TRIFLUOROMETHYL)PHENYLCARBAMOYL-4-AZA-5-AL PHA-ANDROST-1-EN-3-ONE; USED IN THE TREATMENT OF ANDROGEN RESPONSIVE AND MEDIATED DISEASES | GLAXO WELLCOME INC. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1994022900-A1 | AZA-ANDROSTANE-17β-CARBOXAMIDES | CIBA-GEIGY AG (CH) | 1994-10-13 | — | — | WO | disclosed |
| US-5304562-A | Inhibitors of 5-alpha-reductase; treating prostate disorders | CIBA-GEIGY CORPORATION (US) | 1994-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157683-A1 | PROCESS FOR THE PREPARATION OF DUTASTERIDE | CYP21A2, CYP17A1, HSD17B7 | SRD5A1 15/4885SRD5A2 4/4885LMNA 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.